China — National Medical Products Administration
Tracked across 28 events · 196 articles · First seen Apr 08, 2026 · Last active Aug 20, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: The China — National Medical Products Administration (NMPA) accepted the Biologics License Application (BLA) for Lerociclib, which is a crucial regulatory step for the drug's potential approval and availability in China.
Jun 26, 2026 · 8 articles
Regulatory
Impact: The China — National Medical Products Administration granted conditional approval for ORPATHYS (savolitinib) for the treatment of gastric cancer, enabling its commercialization in China.
Jul 02, 2026 · 6 articles
Business
Impact: The China — National Medical Products Administration (NMPA) of China accepted the Investigational New Drug (IND) application for HBM7004, allowing Harbour BioMed to advance its drug towards clinical evaluation in China.
Jun 10, 2026 · 7 articles
Tech
Impact: The China — National Medical Products Administration approved the IND application for ATG-201, enabling Antengene to proceed with Phase I clinical trials in China.
Jun 10, 2026 · 8 articles
Business
Impact: The China — National Medical Products Administration approved Gumokimab, enabling its commercialization in China and providing a new treatment option for patients with moderate-to-severe plaque psoriasis.
Jun 12, 2026 · 7 articles
Regulatory
Impact: The NMPA, through its CDE, granted the BTD, demonstrating its role in facilitating the development of innovative therapies in China. This action reflects the regulatory environment's support for novel cancer treatments.
Aug 03, 2026 · 6 articles
Regulatory
NicOx announced that its exclusive licensee in China, Paragon Therapeutics, has submitted a New Drug Application (NDA) to the Chinese China — National Medical Products Administration (NMPA) for NCX 470, a novel nitric oxide-donating bimatoprost…
Impact: The NMPA is the regulatory authority reviewing the NDA. Its approval decision will determine market access for NCX 470 in China.
Aug 10, 2026 · 6 articles
Tech
Impact: The China — National Medical Products Administration accepted the New Drug Application for fanregratinib and granted it priority review, indicating a potential expedited path to market approval in China.
Jun 24, 2026 · 6 articles
Tech
Impact: The NMPA granted commercial approval to NEO, enabling the first commercial BCI implant and setting a regulatory precedent that may influence future approvals in China.
Jul 06, 2026 · 10 articles
Business
Zylox-Tonbridge Co., Ltd. announced its interim results for the first half of 2026, reporting a 31.1% year-over-year increase in revenue to RMB 632 million and a 47.8% rise in net profit to RMB 179 million.…
Impact: Regulatory body granting approvals for 11 new products, facilitating domestic portfolio expansion and market competitiveness.
Jul 20, 2026 · 7 articles
Business
Impact: NMPA approved the IND application for ATG-201 Phase I study in China, enabling clinical development in the country.
Jul 13, 2026 · 7 articles
Business
Impact: The NMPA's record drug approvals and regulatory reforms create a favorable environment for innovative drug development, indirectly supporting demand for VivoSim's services.
Jul 21, 2026 · 6 articles
Tech
Impact: The NMPA, through its CDE, granted the clinical trial notice, enabling the trial to proceed.
Jul 27, 2026 · 6 articles
Business
Impact: The NMPA approved senaparib in China in January 2025, enabling its commercialization there. This approval is foundational to the drug's global development.
Jul 31, 2026 · 8 articles
Business
Impact: The China — National Medical Products Administration accepted the new drug application for roconkibart in December 2025, indicating progress in the regulatory approval process for the drug.
Jul 01, 2026 · 8 articles
Tech
Impact: The China — National Medical Products Administration (NMPA) of China has granted three Breakthrough Therapy Designations to IBI363, recognizing its potential for significant clinical advantage over existing therapies.
May 21, 2026 · 9 articles
Tech
Impact: The China — National Medical Products Administration (NMPA) of China approved golidocitinib in June 2024 for r/r PTCL, indicating regulatory progress for one of Dizal Pharmaceutical's key assets.
May 31, 2026 · 6 articles
Tech
Impact: The agency has granted sac-TMT six Breakthrough Therapy Designations and accepted a new indication application for review, indicating regulatory recognition of the drug's potential.
May 30, 2026 · 14 articles
Tech
Impact: The China — National Medical Products Administration's Center for Drug Evaluation granted BRII-179 and elebsiran Breakthrough Therapy Designation, and Brii Biosciences has reached preliminary alignment with them regarding a potential registrational study for ENRICH.
Jul 03, 2026 · 7 articles
Tech
Impact: NMPA Class III certification is a regulatory milestone for HAIRO in China.
Jul 10, 2026 · 6 articles
Tech
Impact: The China — National Medical Products Administration is mentioned as having approved AGAMREE for Duchenne muscular dystrophy in China, indicating the drug's established regulatory status.
Jul 01, 2026 · 6 articles
Tech
Impact: China's China — National Medical Products Administration previously approved REDEMPLO (plozasiran), further solidifying its international market approvals.
May 26, 2026 · 6 articles
Business
Impact: The China — National Medical Products Administration approved CardioACC's ICE system in 2025, indicating regulatory acceptance of the technology.
Jun 03, 2026 · 6 articles
Business
Impact: The NMPA approved AGAMREE in China; not directly involved in this expansion.
Jul 13, 2026 · 6 articles
Business
Impact: The NMPA approved lisaftoclax in 2025, but this event does not directly involve the NMPA.
Jul 26, 2026 · 6 articles
ERGEN INTELLIGENCE
Track China — National Medical Products Administration live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard